Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers

NCT01252108 | Withdrawn Phase 2

• 1 other identifier: SQ109-H001
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Helicobacter pylori infection of the gastric epithelium is the most common bacterial infection worldwide. Its global prevalence is estimated at 50%, though the burden falls disproportionately on the developing world, where the prevalence in some areas is 80%. H. pylori infection is generally acquired during childhood, and without specific antibiotic treatment can persist for life. The infection is generally clinically asymptomatic during childhood, and even in adulthood 80-90% of infected individuals will remain asymptomatic (although they may transmit the bacteria). SQ109 is a new, small molecule antibiotic with characteristics that make it particularly attractive to evaluate against H. pylori. In brief, SQ109 is orally bioavailable, acid-stable, has in vitro activity against H. pylori and achieves high intracellular concentration (which may be important to effect bacterial eradication). Based on the antimicrobial activity and clinical safety, SQ109 will be evaluated in this clinical trial to assess safety and antimicrobial activity in adults infected with H. pylori. Data from this study will help determine whether larger safety and efficacy studies in individuals with H. pylori-associated duodenal ulcer disease are warranted.

Conditions

Helicobacter Pylori Infection

Keywords

Helicobacter pylori; peptic ulcer disease; stomach ulcers; gastric cancer

Outcome Measures

Primary Outcomes (1)

• Activity of SQ109 against H. pylori measured by Urea Breath Test Results

  In addition to assessment of safety and tolerability of SQ109, Preliminary efficacy will be assessed by serial Urea Breath Tests during the 14 days of drug administration, and recurrence will be assessed during the 14 days following the last dose of study drug.

  During the 14 days of drug adminstration and 14 days of follow-up

Study Arms (1)

Treatment

EXPERIMENTAL

All subjects receive SQ109

Drug: SQ109

Interventions

SQ109 DRUG

300 mg SQ109 daily for 14 days

Treatment

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subject must be 18 to 45 years of age (inclusive).
• Subject must have 2 positive Urea Breath Tests (UBT) obtaining during screening, and no other clinically significant disease (i.e., hematology, clinical chemistries and urinalysis tests must be within study-defined ranges (See Appendix B). Clinical tests must be performed within 14 days of receiving first dose of study drug.
• Body Mass Index (BMI) must be between 18 and 30 kg/m2 inclusive.
• Subject must be able to give voluntary written informed consent before any study related procedure is performed.
• If female, has no childbearing potential or agrees to avoid becoming pregnant from the day of screening through their entire participation in the trial (Day 42) by using one of the following acceptable methods of birth control plus recommended use of a barrier method (condom) by the male partner (even if vasectomized):
• intrauterine contraceptive device; or
• diaphragm in combination with contraceptive jelly, cream, or foam; or
• spermicide; or
• abstinence.

You may not qualify if:

• A history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which would jeopardize the safety of the subject or impact the validity of the study results.
• Abnormal diet during the 4 weeks preceding the study.
• Use of any OTC or prescription medication, including vitamins and herbal supplements, within 7 days prior to Day 1 of the study, unless the substance would not likely impact on the conduct of this study.
• Current medical condition (other than H. pylori infection) requiring treatment with medication, either prescription or OTC.
• Treatment with any known CYP450 enzyme altering drugs such as azoles, antifungals, barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to Day 1 of the study.
• Positive blood screen for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody and/or a positive urine screen for alcohol or drugs of abuse.
• Baseline QTc interval \>450 msec (males) or \>470 msec (females)or a family history of prolonged QTc syndrome or premature cardiac death.

Sponsors & Collaborators

• Sequella, Inc.: lead

MeSH Terms

Conditions

Peptic Ulcer; Stomach Ulcer; Stomach Neoplasms

Condition Hierarchy (Ancestors)

Duodenal Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Stomach Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms

Study Officials

• Frank Lanza, MD

  Houston Institue for Clinical Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 30, 2010
• First Posted: December 2, 2010
• Study Start: March 1, 2012
• Primary Completion: August 1, 2015
• Study Completion: August 1, 2015
• Last Updated: November 17, 2015

Record last verified: 2015-11